PMID- 23369095
OWN - NLM
STAT- MEDLINE
DCOM- 20131118
LR  - 20191027
IS  - 1873-5576 (Electronic)
IS  - 1568-0096 (Linking)
VI  - 13
IP  - 3
DP  - 2013 Mar
TI  - IDO(+) DCs and signalling pathways.
PG  - 278-88
AB  - Dendritic cells (DCs) have traditionally been viewed as constituting an 
      'information management' system that functions solely to integrate a diverse 
      array of incoming signals, in order to induce immune reactivity. In recent years, 
      however, there has been a shift towards viewing these cells as key regulators in 
      the orchestration of immunological tolerance, with increasing recognition that 
      they are capable of suppressing T-cell responses depending on signalling 
      processes and localised biochemical conditions. Indoleamine 2,3-dioxygenase (IDO) 
      competent (IDO(+)) DCs are a subset of human DCs which are programmed to a 
      tolerogenic state and play a vital role in establishing and maintaining a 
      tumour-suppressing milieu. The expression of IDO in these DCs represents a key 
      mechanism responsible for inducing the tolerogenic state. However, the mechanisms 
      by which IDO becomes dysregulated in this subset of DCs have not yet been 
      described. In this review, the function of IDO(+) DCs within the cancer-tolerogenic 
      milieu, as well as the signals responsible for expression of IDO in this subset, 
      will be discussed.
FAU - Wang, Yue
AU  - Wang Y
AD  - Department of Immunology, Tianjin Medical University cancer institute and 
      hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Key 
      Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, 
      Ministry of Education, Huanhuxi Road, Hexi District, Tianjin 300060, China.
FAU - Yang, Bao-Hong
AU  - Yang BH
FAU - Li, Hui
AU  - Li H
FAU - Cao, Shui
AU  - Cao S
FAU - Ren, Xiu-Bao
AU  - Ren XB
FAU - Yu, Jin-Pu
AU  - Yu JP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Curr Cancer Drug Targets
JT  - Current cancer drug targets
JID - 101094211
RN  - 0 (Antineoplastic Agents)
RN  - 0 (CTLA-4 Antigen)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Indoleamine-Pyrrole 2,3,-Dioxygenase)
RN  - 0 (NF-kappa B)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Protein Isoforms)
RN  - 0 (STAT Transcription Factors)
RN  - 0 (Transforming Growth Factor beta)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - CTLA-4 Antigen/metabolism
MH  - Cell Transformation, Neoplastic/drug effects/metabolism
MH  - Dendritic Cells/drug effects/*immunology/metabolism
MH  - Enzyme Inhibitors/pharmacology/therapeutic use
MH  - Humans
MH  - Immune Tolerance/drug effects
MH  - Immunologic Surveillance/drug effects
MH  - Indoleamine-Pyrrole 2,3,-Dioxygenase/antagonists & 
      inhibitors/chemistry/*metabolism
MH  - NF-kappa B/metabolism
MH  - Neoplasm Proteins/agonists/antagonists & inhibitors/metabolism
MH  - Neoplasms/drug therapy/immunology/metabolism/prevention & control
MH  - Protein Isoforms/metabolism
MH  - STAT Transcription Factors/metabolism
MH  - *Signal Transduction/drug effects
MH  - Transforming Growth Factor beta/metabolism
MH  - Tumor Microenvironment/drug effects
EDAT- 2013/02/02 06:00
MHDA- 2013/11/19 06:00
CRDT- 2013/02/02 06:00
PHST- 2012/06/14 00:00 [received]
PHST- 2012/09/03 00:00 [revised]
PHST- 2013/01/10 00:00 [accepted]
PHST- 2013/02/02 06:00 [entrez]
PHST- 2013/02/02 06:00 [pubmed]
PHST- 2013/11/19 06:00 [medline]
AID - CCDT-EPUB-20130114-1 [pii]
AID - 10.2174/15680096113139990073 [doi]
PST - ppublish
SO  - Curr Cancer Drug Targets. 2013 Mar;13(3):278-88. doi: 
      10.2174/15680096113139990073.